You are here


PLEASE NOTE: All assets on this page are intended for use by media professionals.

Pfizer at ESMO

Pfizer Oncology will present new data from several studies evaluating our broad-based oncology portfolio at the European Society for Medical Oncology (ESMO) 2016 Congress in Copenhagen from October 7-11, 2016. Below please find more information on Pfizer Oncology and the multiple oncology programs being showcased at ESMO.

Press Releases

Pfizer to Showcase Progress of Broad-Based Oncology Portfolio at European Society for Medical Oncology (ESMO) 2016 Congress
Pfizer Presents Promising New Immunotherapy Combination Data With INLYTA® (axitinib) In Advanced Renal Cell Carcinoma (RCC)
First Positive Phase 3 Results In Adjuvant Setting For Renal Cell Carcinoma Show SUTENT® (sunitinib) Extended Disease Free Survival After Surgical Removal

Blocks after Body

Hear from Pfizer Leadership

pricing_albert_bourla.png The Economics of Optimism: Recognizing the Value of Oncology Innovation » Albert Bourla

Group President, Pfizer Global Innovative Pharma, Global Vaccines, Oncology and Consumer Healthcare

collaboration_liz_barrett.png The Science of Optimism, The Wisdom of Collaboration » Liz Barrett

President and General Manager, Pfizer Oncology

combination_trials_mace_rothenberg.png Why the One-Drug, One-Disease Approach Isn’t Enough:
The New Age of Cancer
Therapy »
Mace Rothenberg, MD

Chief Development Officer,
Pfizer Global Product Development

confirmatory_trials_maria_koehler.png The Patient-Centered Approach to Drug Development » Maria Koehler, MD, PhD

Vice President of Strategy, Innovation and Collaborations for Pfizer Oncology

Pfizer Immuno-oncology Video

Recent immunotherapy advances represent new hope for patients with cancer. At Pfizer, we’re primed to go further – and take the next big leap in immuno-oncology.